The Menarini Group
  1. Companies
  2. The Menarini Group
  3. Products
  4. Model MEN1703 - Dual Kinase Inhibitor

Model MEN1703 - Dual Kinase Inhibitor

SHARE

MEN1703 is a dual kinase inhibitor targeting PIM (PIM1, PIM2, PIM 3) and FLT3 kinases. FLT3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in acute myeloid leukemia patients (AML) and is associated with a poor prognosis. PIM kinases are thought to be one of the major drivers of the resistance phenotype to FLT3 inhibitors and their inhibition in relapsed samples restores cell sensitivity to FLT3 inhibitors these agents.

Most popular related searches

The spectrum of activity of MEN1703 also warrants the compound investigation in AML patients regardless of FLT3 aberrations.

MEN1703 is being investigated as potential treatment for adult patients with relapsed/refractory AML.